In focus: (166) Ho-DOTMP in the pretransplant treatment of multiple myeloma.

Abstract

NeoRx STR 0303: a randomized multicenter study to compare the safety and efficacy of (166) HO-DOTMP plus melphalan to melphalan alone as conditioning for autologous peripheral blood stem cell transplant in subjects with primary refractory multiple myeloma.

• Authors: Kathleen Clapp
• Journal: Clinical advances in hematology & oncology : H&O (Clin Adv Hematol Oncol) Vol. 2 Issue 11 Pg. 753-4 (Nov 2004) ISSN: 1543-0790 [Print] United States
• PMID: 16170894 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents, Alkylating
• Organometallic Compounds
• Organophosphorus Compounds
• holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid)
• Melphalan

Topics

• Antineoplastic Agents, Alkylating (administration & dosage, therapeutic use)
• Clinical Trials, Phase III as Topic
• Hematopoietic Stem Cell Transplantation
• Humans
• Melphalan (administration & dosage, therapeutic use)
• Multicenter Studies as Topic
• Multiple Myeloma (drug therapy)
• Organometallic Compounds (therapeutic use)
• Organophosphorus Compounds (therapeutic use)
• Randomized Controlled Trials as Topic
• Transplantation Conditioning